Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZUTXW)

Drug Name

GSK1511931 Drug Info

Synonyms

GSK1511931A; GSK-1511931; compound 14 [PMID: 19081716]

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting IGF1R messenger RNA (IGF1R mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATL-1101	DM4XZU2	Psoriatic disorder	EA90	Preclinical	[2]
GSK-1838705A	DM4HLK3	Discovery agent	N.A.	Investigative	[3]
AZD3463	DMAX9C3	Discovery agent	N.A.	Investigative	[4]
AG 1024	DMF0SPB	Discovery agent	N.A.	Investigative	[5]
PQ401	DMVNHTE	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway. Bioorg Med Chem Lett. 2009 Jan 15;19(2):373-7.
2	Clinical pipeline report, company report or official report of Antisense Therapeutics.
3	Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1801).
5	Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology. 1997 Apr;138(4):1427-33.
6	Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther. 2006 Apr;5(4):1079-86.